Trial Profile

Omalizumab as Monotherapy and as Adjunct Therapy to Multi-Allergen Oral Immunotherapy (OIT) in Food Allergic Children and Adults (CoFAR-11)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Omalizumab (Primary)
Indications Peanut hypersensitivity
Focus Therapeutic Use
Acronyms CoFAR-11; OUtMATCH

Most Recent Events

02 Mar 2025 According to Genentech Media Release, data from the study were presented at the 2025 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting.
02 Mar 2025 Results from Stage 2 and Stage 3 presented in the Genentech Media Release.
28 Jan 2025 Planned End Date changed from 1 Feb 2026 to 30 Jun 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com